← FDA DRUG APPROVALS

FDA ANDA · ANDA200170

DOXORUBICIN HYDROCHLORIDE

Sponsor: MYLAN LABS LTD

APPLICATION
ANDA200170
TYPE
ANDA
ORIGINAL APPROVAL
2011-10-28
LATEST ACTION
2014-11-03
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued, Prescription

Products

DOXORUBICIN HYDROCHLORIDEDiscontinued
DOXORUBICIN HYDROCHLORIDE 10MG/VIAL · INJECTABLE · INJECTION
DOXORUBICIN HYDROCHLORIDEPrescription
DOXORUBICIN HYDROCHLORIDE 50MG/VIAL · INJECTABLE · INJECTION

Approval history

2014-11-03Labeling · Supplement 2 · standardAP
2012-02-28Labeling · Supplement 1AP
2011-10-28Not Applicable · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →